4-[3-(2-nitro-1-imidazolyl)propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive agent as radiosensitizer in vitro and in vivo: Comparison with tirapazamine

Oncology Research

Volumn 12, Issue 8, 2000, Pages 325-333

  Papadopoulou, Maria V ^a   Ji, Ming ^a   Rao, Mira K ^a   Bloomer, William D ^a  

^a EVANSTON NORTHWESTERN HEALTHCARE   (United States)

Author keywords

Bioreductive drugs; Hypoxic cytotoxins; NLCQ 1; Radiosensitizers; Tirapazamine

Indexed keywords

4 (3 (2 NITRO 1 IMIDAZOLYL) PROPYLAMINO) 7 CHLOROQUINOLINE HYDROCHLORIDE; 4-(3-(2-NITRO-1-IMIDAZOLYL)-PROPYLAMINO)-7-CHLOROQUINOLINE HYDROCHLORIDE; ANTINEOPLASTIC AGENT; CYTOTOXIN; IMIDAZOLE DERIVATIVE; QUINOLINE DERIVATIVE; RADIOSENSITIZING AGENT; TIRAPAZAMINE; TRIAZINE DERIVATIVE;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; C3H MOUSE; CELL CULTURE; CELL HYPOXIA; CELL LINE; CELL SURVIVAL; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG SCREENING; EXPERIMENTAL NEOPLASM; FEMALE; HAMSTER; METABOLISM; MOUSE; PATHOLOGY; RADIATION RESPONSE; SQUAMOUS CELL CARCINOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL HYPOXIA; CELL LINE; CELL SURVIVAL; CRICETINAE; CYTOTOXINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; DRUG ADMINISTRATION SCHEDULE; FEMALE; IMIDAZOLES; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; NEOPLASMS, EXPERIMENTAL; QUINOLINES; RADIATION-SENSITIZING AGENTS; TRIAZINES; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0034571055     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/096504001108747774     Document Type: Review

References (36)

1. Adam, M.; Gabalski, E. C.; Bloch, D. A.; Oehlert, J. M.; Brown, J. M.; Elsaid, A. A.; Pinto, H. A.; Terris, D. J. Tissue oxygen distribution in head and neck cancer patients. Head Neck 21:146-153; 1999.
2. Fyles, A. W.; Milosevic, M.; Wong, R.; Kavanagh, M. C.; Pintilie, M.; Sun, A.; Chapman, W.; Levin, W.; Manchul, L.; Keane, T. J.; Hill, R. P. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother. Oncol. 48:149-156; 1998.
3. Brizel, D. M.; Sibley, G. S.; Prosnitz, L. R.; Scher, R. L.; Dewhirst, M. W. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int. J. Radiat. Oncol. Biol. Phys. 38:285-289; 1997.
4. Sundfor, K.; Lyng, H.; Rofstad, E. K. Tumour hypoxia and vascular density as predictors of metastasis in squamous cell carcinoma of the uterine cervix. Br. J. Cancer 78:822-827; 1998.
5. Brizel, D. M.; Scully, S. P.; Harrelson, J. M.; Layfield, L. J.; Bean, J. M.; Prosnitz, L. R.; Dewhirst, M. W. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res. 56:941-943; 1996.
6. Denny, W. A.; Wilson, W. R. Bioreducible mustards: A paradigm for hypoxia-selective prodrugs of diffusible cytotoxins (HPDCs). Cancer Metastasis Rev. 12:135-151; 1993.
7. Brown, J. M.; Giaccia, A. J. Tumour hypoxia: The picture has changed in the 1990s. Int. J. Radiat. Biol. 65:95-102; 1994.
8. Workman, P.; Stratford, I. J. The experimental development of bioreductive drugs and their role in cancer therapy. Cancer Metastasis Rev. 12:73-82; 1993.
9. Brown, J. M.; Koong, A. Therapeutic advantage of hypoxic cells in tumors: A theoretical study. J. Natl. Cancer Inst. 83:178-185; 1991.
10. Haffty, B. G.; Son, Y. H.; Sasaki, C. T.; Papac, R.; Fischer, D.; Rockwell, S.; Sartorelli, A.; Fischer, J. J. Mitomycin C as an adjunct to postoperative radiation therapy in squamous cell carcinoma of the head and neck: Results from two randomized clinical trials. Int. J. Radiat. Oncol. Biol. Phys. 27:241-250; 1993.
11. Lee, D-J.; Trotti, A.; Spencer, S.; Rostock, R.; Fisher, C.; von Roemeling, R.; Harvey, E.; Groves, E. Concurrent tirapazamine and radiotherapy for advanced head and neck carcinomas: A Phase II study. Int. J. Radiat. Oncol. Biol. Phys. 42:811-815; 1998.
12. Overgaard, J.; Hansen, H. S.; Overgaard, M.; Bastholt, L.; Berthelsen, A.; Specht, L.; Lindelov, B.; Jorgensen, K. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHNCA) Protocol 5-85. Radiother. Oncol. 46:135-146; 1998.
13. Papadopoulou, M. V.; Rosenzweig, H. S.; Doddi, M.; Bloomer, W. D. 9-(3-(2-Nitro-1-imidazolyl)-propylamino)-1,2,3,4-tetrahydroacridine hydrochloride. A novel DNA-affinic hypoxic cell cytotoxin and radiosensitizer. Comparison with NLA-1. Oncol. Res. 6:439-448; 1994.
14. Papadopoulou, M. V.; Rosenzweig, H. S.; Doddi, D.; Bloomer, W. D. S-THNLA-1 and MeN-THNLA-1. Two new bioreductive agents as radiosensitizers and selective cytotoxins of hypoxic cells. Proceedings of International Conference on Bioreductive Drug Activation, Granlibakken Conference Center, Lake Tahoe, CA, August 16-19, 1994.
15. Papadopoulou, M. V.; Ji, M.; Bloomer, W. D. THNLA-1: A DNA-targeted bioreductive agent as chemosensitizer in vitro and in vivo. In Vivo 10:49-58; 1996.
16. Papadopoulou, M. V.; Ji, M.; Bloomer, W. D. THNLA-1 as radio/ chemosensitizer of EMT-6 tumors in mice. Br. J. Cancer 74(Suppl. XXVII):S267-S270; 1996.
17. Papadopoulou, M. V.; Ji, M.; Rao, M. K.; Bloomer, W. D. 9-[3-(2-Nitro-1-imidazolyl)-propylamino]-cyclopenteno[b]quinoline hydrochloride (NLCPQ-1). A novel DNA-affinic bioreductive agent as cytotoxin and radiosensitizer. Oncol. Res. 8:425-434; 1996.
18. Papadopoulou, M. V.; Ji, M.; Rao, M. K.; Bloomer, W. D. 9-[3-(2-Nitro-1-imidazolyl)-propylamino] cyclopenteno[b]quinoline hydrochloride (NLCPQ-1). A novel DNA-affinic bioreductive agent as chemosensitizer. I. Oncol. Res. 9:249-257; 1997.
19. Papadopoulou, M. V.; Ji, M.; Rao, M. K.; Bloomer, W. D 4-[3-(2-Nitro-1-imidazolyl)-propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive compound as a hypoxia-selective cytotoxin. Oncol. Res. 12:185-192; 2001.
20. Hay, M. P.; Wilson, W. R.; Moselen, J. W.; Palmer, B. D.; Denny, W. A. Hypoxia-selective antitumor agents. 8. Bis(nitroimidazolyl)-alkanecarboxamides: A new class of hypoxia-selective cytotoxins and hypoxic cell radiosensitisers. J. Med. Chem. 37:381; 1994.
21. Papadopoulou, M. V.; Ji, M.; Bloomer, W. D. NLCQ-1, a novel hypoxic cytotoxin: Potentiation of melphalan, cisDDP and cyclophosphamide in vivo. Int. J. Radiat. Oncol. Biol. Phys. 42:775-779; 1998.
22. Papadopoulou, M. V.; Ji, M.; Bloomer, W. D. Potentiation of chemotherapeutic drugs by the bioreductive compound NLCQ-1 against SCCVII tumors in mice. Proc. Am. Assoc. Cancer Res. Annu. Meet. 41:766-767; 2000.
23. Lee, A. E.; Wilson, W. R. Hypoxia-dependent retinal toxicity of bioreductive anticancer prodrugs in mice. Toxicol. Appl. Pharmacol. 163:50-59; 2000.
24. Squillace, D. P.; Ruben, S. L.; Reid, J. M.; Ames, M. M. HPLC analysis and murine pharmacokinetics of the cytotoxic bioreductive agent NLCQ-1 (NSC 709257). Proc. Am. Assoc. Cancer Res. Annu. Meet. 41:706; 2000.
25. Rockwell, S. C.; Kallman, R. F.; Fajardo, L. F. Characteristics of a serially transplanted mouse mammary tumor and its tissue-culture-adapted derivative. J. Natl. Cancer Inst. 49:735; 1972.
26. Hirst, D. G.; Brown, J. M.; Hazlehurst, J. L. Effect of partition coefficient on the ability of nitroimidazoles to enhance the cytotoxicity of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea. Cancer Res. 43:1961-1965; 1983.
27. Wilson, W. R.; Siim, B. G.; Denny, W. A.; VanZijl, P. L.; Taylor, M. L.; Chambers, D. M.; Roberts, P. B. 5-Nitro-4-(N,N-dimethylaminopropyl-amino)quinoline (5-nitraquine), a new DNA-affinic hypoxic cell radiosensitizer and bioreductive agent: Comparison with nitracrine. Radiat. Res. 131:257-265; 1992.
28. Brown, M. J.; Lemmon, M. J. Potentiation by the hypoxic cytotoxin SR4233 of cell killing produced by fractionated irradiation of mouse tumors. Cancer Res. 50:7745-7749; 1990.
29. Roberts, P. B.; Denny, W. A.; Wakelin, L. P. G.; Anderson, R. F.; Wilson, W. R. Radiosensitization of mammalian cells in vitro by nitroacridines. Radiat. Res. 123:153-164; 1990.
30. Dorie, M. J.; Brown, M. J. Modification of the antitumor activity of chemotherapeutic drugs by the hypoxic cytotoxic agent tirapazamine. Cancer Chemother. Pharmacol. 39:361-366; 1997.
31. Aboagye, E. O.; Maxwell, R. J.; Kelson, A. B.; Tracy, M.; Lewis, A. D.; Graham, M. A.; Horsman, M. R.; Griffiths, J. R.; Workman, P. Preclinical evaluation of fluorinaled 2-nitroimidazole N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR-4554) as a probe for measurement of tumor hypoxia. Cancer Res. 57:3314-3318; 1997.
32. Hill, R. P. Sensitizers and radiation dose fractionation: Results and interpretations. Int. J. Radiat. Oncol. Biol. Phys. 12:1049-1054; 1986.
33. Zeman, E. L.; Brown, M. J.; Lemmon, M. J.; Hirst, K. V.; Lee, W. W. SR-4233: A new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int. J. Radiat. Oncol. Biol. Phys. 12:1239-1242; 1986.
34. Zeman, E. L.; Hirst, K. V.; Lemmon, M. J.; Brown, M. J. Enhancement of radiation-induced tumor cell killing by the hypoxic cell toxin SR 4233. Radiother. Oncol. 12:209-218; 1988.
35. Kallman, R. F.; Done, M. J. Tumor oxygenation and reoxygenation during radiation therapy: Their importance in predicting tumor response. Int. J. Radiat. Oncol. Biol. Phys. 12:681-685; 1986.
36. Goda, F.; O'Hara, J. A.; Rhodes, E. S.; Liu, K. J.; Dunn, J. F.; Bacic, G.; Swartz, H. M. Changes of oxygen tension in experimental tumors after a single dose of X-ray irradiation. Cancer Res. 55:2249-2252; 1995.